CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma
Glioblastoma is the most aggressive primary brain tumor with limited efficacy of established therapies, and a pronounced immunosuppressive tumor microenvironment. Targeting HER2 with local immunotherapy allows for high tumor specificity in the brain with physiologically very low expression. Monother...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
18 May 2025
|
| In: |
British journal of cancer
Year: 2025, Volume: 132, Issue: 9, Pages: 849-860 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/s41416-025-02977-8 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41416-025-02977-8 Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41416-025-02977-8 |
| Author Notes: | F. Strassheimer, P. Elleringmann, G. Ludmirski, B. Roller, J. Macas, T. Alekseeva, P. Cakmak, B. Aliraj, H. Krenzlin, M. C. Demes, I. C. Mildenberger, T. Tonn, K. J. Weber, Y. Reiss, K. H. Plate, A. Weigert, W. S. Wels, J. P. Steinbach and M. C. Burger |
| Summary: | Glioblastoma is the most aggressive primary brain tumor with limited efficacy of established therapies, and a pronounced immunosuppressive tumor microenvironment. Targeting HER2 with local immunotherapy allows for high tumor specificity in the brain with physiologically very low expression. Monotherapy with CAR-NK cells targeted against HER2 has previously shown efficacy in medium-sized GL261/HER2 tumors. |
|---|---|
| Item Description: | Online veröffentlicht: 18. März 2025 Gesehen am 05.08.2025 |
| Physical Description: | Online Resource |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/s41416-025-02977-8 |